Latest News
Perspective Therapeutics, Inc.
- Form 8K Perspective Therapeutics Inc For: 23 October By Investing.com
- Perspective Therapeutics reports interim trial results for NET cancer treatment By Investing.com
- Perspective Therapeutics Reports VMT-α-NET Responses of 33% and 50% in Phase 1/2a Trial
- Perspective Therapeutics (CATX) Gets a Hold from Bank of America Securities
- Perspective Therapeutics wins FDA Fast Track for PSV359 alpha-particle therapy in rare sarcoma
- Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors
- Perspective Therapeutics Announces NANETS 2026 Presentation of [212Pb]VMT-α-NET Clinical Data in Advanced Neuroendocrine Tumors
- Perspective Therapeutics Announces Acceptance of [212Pb]VMT01 Data for Presentation at SITC 2026
- Form 13D/A Perspective Therapeutics For: 26 September By Investing.com
Headlines from the last 30 days, linking to the original publishers. See all market news →